iZafe Group AB (publ) – announces that in connection with the interim report for the second quarter of 2022, which will be published at 08:30 CET on August 26, 2022, shareholders, media, and other stakeholders will be given the opportunity to ask questions to the company.

The questions will be answered by CEO Anders Segerström and published on iZafe Group's investor page on September 2, 2022, under the heading financial reports, investor questions.
Please send your questions to before 10:00 CET (10 a.m.) on August 30, 2022.

iZafe Group (publ.) hereby invites you to a live interview with Pilloxa's CEO Helena Rönnqvist and iZafe Group's CEO Anders Segerström on Wednesday, August 24 at 2 p.m. due to the fact that iZafe has signed a letter of intent with Pilloxa to acquire 100 percent of the shares in Pilloxa.

Read the full news here.

During the interview, all shareholders and stakeholders will get a more in-depth understanding of the rationale behind the acquisition, about Pilloxa as a company and what the acquisition means for the future iZafe Group.

Links to the interview can be found here
LinkedIn
Facebook

Stockholm – iZafe Group (publ.) Announces today that it has delivered an additional 100 Dosell units to Apoteket AB in addition to deliveries of 130 units earlier in June. A total of 230 units were now delivered during the month of June to Apoteket AB.

– The great demand is a proof that more and more people want to use new digital technology in their daily lives to free up time and ensure compliance in their or their relatives medication. It also shows that Apoteket's online store is a good way to reach those who want safer drug handling at home, says Anders Segerström, CEO of iZafe Group AB.
 
This summer, iZafe will release a new feature in the Dosell app that makes it even easier to follow up on your own or relatives medication.
 
– This new function makes it even easier to follow your own or your relatives medication. We also know that the opportunity to test Dosell contributes to the experience of what a difference Dosell really makes. Therefore, we will in the TV commercial highlight that you get the opportunity to send Dosell back within 30 days if you are not satisfied with the product. This is so that even more people will dare to take the step of testing new digital technology that frees up time and ensures compliance in their or their relatives medication, says Anders Segerström, CEO of iZafe Group AB.
 
– The consumer version of Dosell is unique and currently Europe's only pharmaceutical robot for the private market based on dose bags. This has attracted the attention of several players where dialogues are now being conducted to launch Dosell for consumers in several markets in Europe, says Anders Segerström, CEO of iZafe Group AB.

iZafe Group (publ.) hereby announces that a large amount of Dosell will be delivered from the factory to Apoteket AB today, after being out of stock for about 6 weeks.

“We are pleased to be able to refill Apoteket AB's warehouse after Dosell has been sold out for a period. As more and more people use Dosell, we work focused on securing production and improving its functionality.

The latest update contained a bug that caused Dosell to restart from time to time. This has led to delays in deliveries, both of the consumer version and the corporate version, which has affected the municipalities' planned project starts of Dosell. As we approach the holiday season, most municipalities have chosen to postpone the introduction until after the summer.

The new, updated version of Dosell includes several new improvements and features that will improve both the user experience and reliability. Consumers using Dosell will not be affected as the new software is updated over the cloud.” Says Anders Segerström, CEO of iZafe Group AB.

About Dosell
The pharmaceutical robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
It is estimated that 3,000 Swedes die each year from medication-related injuries and 6–16 percent of hospital admissions are medication-related, according to a compilation from the Swedish National Board of Health and Welfare.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing medication-related injuries.
Read more at www.dosell.se

Dosell's business unit manager, Henrik Windahl, has acquired 319,841 shares in the company.

Henrik Windahl, who recently began his employment as department manager for Dosell in iZafe Group's wholly owned subsidiary Dosell AB, has today acquired 319,941 Series B shares in the company to a value of SEK 163,534 (SEK 0.51 / pc).

The Board and management have for a long period developed iZafe Group's vision and strategy. We are now presenting it to shareholders and stakeholders to create an understanding of where iZafe Group is heading as a company.

Today, the company offers a product, Dosell, which is based on ensuring the right medicine at the right time via sachets. However, the importance of good adherence applies to more than those who receive medication via sachets. By broadening our offer from manual medicine management in the mobile app to a comprehensive offer that automates the entire flow with Dosell, iZafe Group becomes the company that helps everyone to take the right medicine at the right time.
 
Our new vision is therefore "health thanks to good adherence."
 
To achieve this, we will develop a comprehensive range of digital services and products that ensure that the right medicine is taken at the right time with the goal of being able to clearly show the health effects of adherence combined with values from other sensors:

  • Our app is the basis for all solutions that can be used together with Dosell, other devices or as a standalone service and should remind and ensure adherence regardless of whether the medicines are packaged in sachets, pill jars, injection, tablet, or in liquid form. It shall also keep statistics and possibly alert in the event of no medication. Alarms can reach the user as well as relatives and / or care staff.
  • Sorting in a container for medicines where we offer a smartly connected version that with the help of our app helps with sorting, reminders, statistics and alarms to selected people in case of missed medication.
  • Medicine in a sachet where we, with the help of Dosell, automate all aspects of the medication.

In this way, we get access to a large amount of data that will help us understand our customers, know when to offer the user products to ensure adherence, create opportunities for new collaborations and a basis for doctors regarding future care interventions or changes in medication.
 
Adherence data is also an important basis for pharmaceutical companies and other stakeholders conducting clinical studies. Therefore, these stakeholders are also a potential stakeholder for iZafe Group.
 
“We are now entering a new phase of our journey towards becoming a market leader to improve adherence and thus health. We must ensure that everyone who medicates has the best conditions to take the right medicine at the right time through smart, digital and modern solutions. During the rest of 2022, we will be able to see several interesting updates in our company to ensure that this further development goes according to plan. We look forward to being able to communicate them in the near future.” says Joachim Källsholm, Chairman of the Board of iZafe Group AB.
 
Linked to the new strategy, several changes are now being implemented within the organization. With the new direction that the company is taking, the board has agreed together with vice president and commercial director Tobias Johansson to go their separate ways.
 
iZafe Group has chosen to recruit Henrik Windahl as Business Unit Manager, who will start on May 30. Henrik's background and extensive experience in partner sales and business development will help to take the company's sales of Dosell to the levels needed to be able to take the next step in iZafe Group's development and success both nationally and internationally.
 
Read iZafe Group's new company narrative here.

iZafe Group AB (publ) – announces that in connection with the interim report for the first quarter of 2022, which will be published at 08:30 CET on April 29, 2022, shareholders, media, and other stakeholders will be given the opportunity to ask questions to the company.

The questions will be answered by CEO Anders Segerström and published on iZafe Group's investor page on May 9, 2022, under the heading financial reports, investor questions.

Please send your questions to before 10:00 CET (10 a.m.) on May 4, 2022.

iZafe Group (publ.) hereby announces that the partner Zafe Care Systems AB has now begun implementation of 2 Dosell in a municipality in northern Sweden.

The municipality, which has about 2,650 inhabitants who are 65 years and older, initially starts with 2 Dosell with an ambition to increase the number gradually.
 
About Zafe
Zafe Care Systems AB, which was acquired by the AddLife Group, is part of Home Care, similar to Norwegian Hepro, and is one of the leading companies in welfare technology on the Swedish market. Their main customers are the state, municipalities and aid centers. Today, they work with more than 200 municipalities and are suitable thanks to their market-leading technology in all types of care homes.
 
About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

iZafe Group (publ.) hereby announces that the partner Hepro AS has now starting implementation of 2 Dosell in a municipality in the southern region of Norway.

The municipality, which has about 3,700 inhabitants who are 65 years and older, initially starts with 2 Dosell with an ambition to increase the number gradually.
 
 
About Hepro
HEPRO AS is a modern and future-oriented competence company that develops, produces and sells aids and welfare technology of high quality and clean design. The company was founded in 1987 and has extensive experience in developing products and solutions that will make everyday life easier for their customers. Their vision is to give their customers the opportunity to manage themselves, participate actively in their own everyday lives and stay longer at home. Hepro is owned by the Stockholm-based listed AddLife Group. AddLife has approx. 70 st. independent subsidiaries and over 1800 employees.
 
About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

iZafe Group (publ.) hereby announces that the partner Careium AB has now begun implementation of 6 Dosell in a municipality in western Sweden.

The municipality, which has about 3,000 inhabitants who are 65 years and older, initially starts with 6 Dosell.
 
About Careium
Careium is today the market leader in welfare technology in Europe and approximately 400,000 people use their services. The vast majority of these are connected to one of their six alarm centers in Sweden, Norway and the United Kingdom. The alarm centers receive more than 30,000 alarms a day.
Doro Care recently changed its name to Careium. Doro acquired Caretech in 2014, which became the starting point for what today is Careium.
 
About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

Webbdesign av Comlog Webbyrå Stockholm